Type 2 diabetes, obesity, and related metabolic diseases all involve abnormalities in glucose homeostasis, pancreatic endocrine function, food intake, and energy balance. GLP-1R can simultaneously regulate insulin secretion, glucagon, gastric emptying, and feeding behavior and has therefore ...
Alzheimer’s disease is jointly driven by Aβ deposition, Tau abnormalities, neuroinflammation, disrupted lipid metabolism, and synaptic injury. Defining the core targets at different pathological stages provides the basis for disease stratification, therapeutic monitoring, and the design of ...
GLP-1R, GIPR, and GCGR jointly regulate pancreatic hormone secretion, hepatic glucose output, feeding behavior, and energy metabolism. Multi-receptor agonists improve the overall metabolic treatment of obesity and type 2 diabetes by balancing glucose-lowering effects, appetite suppression, and ...
Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
Utilizamos cookies para garantizar el correcto funcionamiento del sitio web y, cuando esté permitido, para mejorar su experiencia. Puede gestionar sus preferencias en cualquier momento en Configuración. Más información en nuestra Política de Cookies.
¿Quieres que te enviemos un mensaje cuando tengamos descuentos disponibles?
Recordármelo más tarde
¡Gracias! Por favor, revisa tu bandeja de entrada de correo electrónico para confirmar.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.